|Bid||12.00 x 800|
|Ask||12.40 x 3200|
|Day's Range||11.81 - 12.30|
|52 Week Range||11.35 - 24.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.50|
Dynavax Technologies Corporation (DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to generate durable, systemic anti-tumor immunity. The paper titled Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay, by Dynavax scientists M.Gallotta, H. Assi, E. Degagné, S. Kannan, R.Coffman and C. Guiducci was published in the journal Cancer Research.
Dynavax Technologies Corporation (DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR). The investigators report clinical activity and broad immune activation in the tumor microenvironment when SD-101 is administered in combination with either low dose radiation in patients with indolent lymphoma or in combination with PD-1 blockade in patients with unresectable or metastatic melanoma. “Promising data from multiple trials studying intratumoral administration of TLR9 agonists indicate that stimulating the innate immune system through the TLR9 pathway can enhance the adaptive immune response to both injected and non-injected tumors,” said Antoni Ribas, M.D., Ph.D., Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center.
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National ...
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -6.78% and -24.23%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Berkeley, California-based company said it had a loss of 63 cents. The biopharmaceutical company posted revenue of $1.3 million in the period. Dynavax Technologies shares have ...
HEPLISAV-B ® Launch Progressing as Planned with Key Customer Successes. Three abstracts accepted for presentation at European Society for Medical Oncology 2018 Annual Meeting. Conference Call to be held ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Dynavax Technologies Corporation (NASDAQ: DVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM ...
Dynavax Technologies Corporation (DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018, and host a conference call that day to review the results and provide an update on the launch of HEPLISAV-B® [Hepatitis B Vaccine, (Recombinant) Adjuvanted] and its oncology program at 4:30pm ET/1:30pm PT. To access the call, participants must dial (800) 239-9838 in the U.S. or (323) 794-2551 internationally, and use the conference ID 2303066. The conference ID for the replay will be 2303066.
Jim Cramer recommended on CNBC's "Mad Money Lightning Round" a long position in Childrens Place Inc (NASDAQ: PLCE ). He would buy the weakness in the stock. Dynavax Technologies Corporation (NASDAQ: ...
Jim Cramer rattles off his take on callers' favorite stocks, including his take on how investors should approach the gold market.
On Friday, July 6, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: CytomX Therapeutics Inc. (NASDAQ: CTMX), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), Editas Medicine Inc. (NASDAQ: EDIT).
Dynavax Technologies Corporation (DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in research, development, and commercialization in the fields of oncology and immunology.
In a Post-Hoc Analysis of Elderly Diabetic Patients, HEPLISAV-B was Well-Tolerated and Induced Higher Rates of Seroprotection than Engerix-B. Data Presented at 2018 American Diabetes Association Annual ...
The huge American Society of Clinical Oncology or ASCO confab has called it a wrap for another year. Keytruda to treat PD-1-naive advanced melanoma patients. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017.
Eddie Gray took the helm as Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO and grew market cap to US$993.27M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
The American Society of Clinical Oncology conference -- the biggest event of the year for oncology firms and investors -- kicks off June 1 in Chicago, and scores of firms typically release abstracts right around now of studies that they'll be presenting at the event, which is known as "ASCO." that means a myriad of oncology names have either already moved or will soon do so on these reports. It presented promising data last year around its compound larotrectinib -- news that eventually parlayed its way into a $1.5 billion collaboration deal with Bayer. This year, Loxo will report that an early stage Phase 1 trial involved a compound called LOXO-292 showed a 69% overall response rate among RET-positive patients with non-small-cell lung cancer and a type of thyroid cancer.
Assessing Dynavax Technologies Corporation’s (NASDAQ:DVAX) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...